Jasart Byron Gesso

Jasco Pty Limited

Chemwatch Hazard Alert Code: **3**

Chemwatch: **5590-42**
Version No: **2.1**
Safety Data Sheet according to WHS Regulations (Hazardous Chemicals) Amendment 2020 and ADG requirements

Issue Date: **24/02/2023**
Print Date: **24/02/2023**
L.GHS.AUS.EN

SECTION 1 Identification of the substance / mixture and of the company / undertaking

Product Identifier

Product name	Jasart Byron Gesso
Chemical Name	Not Applicable
Synonyms	0104710, JASART BYRON GESSO 250ML WHT; 0104720, JASART BYRON GESSO 500ML WHT; 0104730, JASART BYRON GESSO 1L WHT
Chemical formula	Not Applicable
Other means of identification	Not Available

Relevant identified uses of the substance or mixture and uses advised against

Relevant identified uses	Painting materials. Use according to manufacturer's directions.

Details of the manufacturer or supplier of the safety data sheet

Registered company name	**Jasco Pty Limited**
Address	1-5 Commercial Road Kingsgrove NSW 2208 Australia
Telephone	+61 2 9807 1555
Fax	Not Available
Website	www.jasco.com.au
Email	sales@jasco.com.au

Emergency telephone number

Association / Organisation	**Australian Poisons Centre**	**CHEMWATCH EMERGENCY RESPONSE (24/7)**
Emergency telephone numbers	13 11 26 (24/7)	+61 1800 951 288
Other emergency telephone numbers	Not Available	+61 3 9573 3188

Once connected and if the message is not in your preferred language then please dial 01

SECTION 2 Hazards identification

Classification of the substance or mixture

Poisons Schedule	Not Applicable
Classification [1]	Skin Corrosion/Irritation Category 2, Serious Eye Damage/Eye Irritation Category 2A, Specific Target Organ Toxicity - Single Exposure (Respiratory Tract Irritation) Category 3, Germ Cell Mutagenicity Category 2, Carcinogenicity Category 1A
Legend:	*1. Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI*

Label elements

Page 1 continued...

Hazard pictogram(s)	
Signal word	**Danger**

Hazard statement(s)

H315	Causes skin irritation.
H319	Causes serious eye irritation.
H335	May cause respiratory irritation.
H341	Suspected of causing genetic defects.
H350	May cause cancer.

Precautionary statement(s) Prevention

P201	Obtain special instructions before use.
P271	Use only outdoors or in a well-ventilated area.
P280	Wear protective gloves, protective clothing, eye protection and face protection.
P261	Avoid breathing mist/vapours/spray.
P264	Wash all exposed external body areas thoroughly after handling.

Precautionary statement(s) Response

P308+P313	IF exposed or concerned: Get medical advice/ attention.
P305+P351+P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P312	Call a POISON CENTER/doctor/physician/first aider/if you feel unwell.
P337+P313	If eye irritation persists: Get medical advice/attention.
P302+P352	IF ON SKIN: Wash with plenty of water.
P304+P340	IF INHALED: Remove person to fresh air and keep comfortable for breathing.
P332+P313	If skin irritation occurs: Get medical advice/attention.
P362+P364	Take off contaminated clothing and wash it before reuse.

Precautionary statement(s) Storage

P405	Store locked up.
P403+P233	Store in a well-ventilated place. Keep container tightly closed.

Precautionary statement(s) Disposal

P501	Dispose of contents/container to authorised hazardous or special waste collection point in accordance with any local regulation.

SECTION 3 Composition / information on ingredients

Substances

See section below for composition of Mixtures

Mixtures

CAS No	%[weight]	Name
25035-69-2	30-50	butyl acrylate/ methyl methacrylate/ methacrylic acid pol.
13463-67-7	20-30	titanium dioxide
7000-29-5	10-20	dolomite
25265-77-4	1-5	2,2,4-trimethyl-1,3-pentanediol monoisobutyrate
7446-81-3	0.1-1	acrylic acid, sodium salt
9003-13-8	0.1-0.8	polypropylene glycol monobutyl ether
25322-68-3	0.1-0.8	polyethylene glycol
124-68-5	0.1-0.5	monoisobutanolamine

Continued...

CAS No	%[weight]	Name
65996-95-4	0.1-0.5	superphosphates, concentrated
7732-18-5	10-15	water

Legend:	*1. Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI; 4. Classification drawn from C&L; * EU IOELVs available*

SECTION 4 First aid measures

Description of first aid measures

Eye Contact	If this product comes in contact with the eyes: ▸ Wash out immediately with fresh running water. ▸ Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids. ▸ Seek medical attention without delay; if pain persists or recurs seek medical attention. ▸ Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.
Skin Contact	If skin contact occurs: ▸ Immediately remove all contaminated clothing, including footwear. ▸ Flush skin and hair with running water (and soap if available). ▸ Seek medical attention in event of irritation.
Inhalation	▸ If fumes or combustion products are inhaled remove from contaminated area. ▸ Lay patient down. Keep warm and rested. ▸ Prostheses such as false teeth, which may block airway, should be removed, where possible, prior to initiating first aid procedures. ▸ Apply artificial respiration if not breathing, preferably with a demand valve resuscitator, bag-valve mask device, or pocket mask as trained. Perform CPR if necessary. ▸ Transport to hospital, or doctor, without delay.
Ingestion	▸ Immediately give a glass of water. ▸ First aid is not generally required. If in doubt, contact a Poisons Information Centre or a doctor. ▸ If spontaneous vomiting appears imminent or occurs, hold patient's head down, lower than their hips to help avoid possible aspiration of vomitus.

Indication of any immediate medical attention and special treatment needed

Treat symptomatically.

SECTION 5 Firefighting measures

Extinguishing media

- Alcohol stable foam.
- Dry chemical powder.
- BCF (where regulations permit).
- Carbon dioxide.
- Water spray or fog - Large fires only.

Special hazards arising from the substrate or mixture

Fire Incompatibility	▸ Avoid contamination with oxidising agents i.e. nitrates, oxidising acids, chlorine bleaches, pool chlorine etc. as ignition may result

Advice for firefighters

Fire Fighting	▸ Alert Fire Brigade and tell them location and nature of hazard. ▸ Wear breathing apparatus plus protective gloves in the event of a fire. ▸ Prevent, by any means available, spillage from entering drains or water courses. ▸ Use fire fighting procedures suitable for surrounding area. ▸ **DO NOT** approach containers suspected to be hot. ▸ Cool fire exposed containers with water spray from a protected location. ▸ If safe to do so, remove containers from path of fire. ▸ Equipment should be thoroughly decontaminated after use.
Fire/Explosion Hazard	carbon dioxide (CO_2) nitrogen oxides (NOx) phosphorus oxides (POx) silicon dioxide (SiO_2) metal oxides other pyrolysis products typical of burning organic material. May emit poisonous fumes.

Continued...

	May emit corrosive fumes. Decomposes on heating and produces toxic fumes of:
HAZCHEM	Not Applicable

SECTION 6 Accidental release measures

Personal precautions, protective equipment and emergency procedures

See section 8

Environmental precautions

See section 12

Methods and material for containment and cleaning up

Minor Spills	‣ Clean up all spills immediately. ‣ Avoid contact with skin and eyes. ‣ Wear impervious gloves and safety goggles. ‣ Trowel up/scrape up. ‣ Place spilled material in clean, dry, sealed container. ‣ Flush spill area with water.
Major Spills	Minor hazard. ‣ Clear area of personnel. ‣ Alert Fire Brigade and tell them location and nature of hazard. ‣ Control personal contact with the substance, by using protective equipment as required. ‣ Prevent spillage from entering drains or water ways. ‣ Contain spill with sand, earth or vermiculite. ‣ Collect recoverable product into labelled containers for recycling. ‣ Absorb remaining product with sand, earth or vermiculite and place in appropriate containers for disposal. ‣ Wash area and prevent runoff into drains or waterways. ‣ If contamination of drains or waterways occurs, advise emergency services.

Personal Protective Equipment advice is contained in Section 8 of the SDS.

SECTION 7 Handling and storage

Precautions for safe handling

Safe handling	‣ Avoid all personal contact, including inhalation. ‣ Wear protective clothing when risk of exposure occurs. ‣ Use in a well-ventilated area. ‣ Prevent concentration in hollows and sumps. ‣ **DO NOT** enter confined spaces until atmosphere has been checked. ‣ **DO NOT** allow material to contact humans, exposed food or food utensils. ‣ Avoid contact with incompatible materials. ‣ When handling, **DO NOT** eat, drink or smoke. ‣ Keep containers securely sealed when not in use. ‣ Avoid physical damage to containers. ‣ Always wash hands with soap and water after handling. ‣ Work clothes should be laundered separately. Launder contaminated clothing before re-use. ‣ Use good occupational work practice. ‣ Observe manufacturer's storage and handling recommendations contained within this SDS. ‣ Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions are maintained.
Other information	‣ Store in original containers. ‣ Keep containers securely sealed. ‣ Store in a cool, dry, well-ventilated area. ‣ Store away from incompatible materials and foodstuff containers. ‣ Protect containers against physical damage and check regularly for leaks. ‣ Observe manufacturer's storage and handling recommendations contained within this SDS.

Conditions for safe storage, including any incompatibilities

Suitable container	‣ Polyethylene or polypropylene container. ‣ Packing as recommended by manufacturer. ‣ Check all containers are clearly labelled and free from leaks.
Storage incompatibility	‣ Avoid strong acids, bases.

Continued...

SECTION 8 Exposure controls / personal protection

Control parameters

Occupational Exposure Limits (OEL)

INGREDIENT DATA

Source	Ingredient	Material name	TWA	STEL	Peak	Notes
Australia Exposure Standards	titanium dioxide	Titanium dioxide	10 mg/m3	Not Available	Not Available	(a) This value is for inhalable dust containing no asbestos and < 1% crystalline silica.

Emergency Limits

Ingredient	TEEL-1	TEEL-2	TEEL-3
titanium dioxide	30 mg/m3	330 mg/m3	2,000 mg/m3
2,2,4-trimethyl-1,3-pentanediol monoisobutyrate	13 mg/m3	140 mg/m3	840 mg/m3
polypropylene glycol monobutyl ether	27 mg/m3	300 mg/m3	1,800 mg/m3
polyethylene glycol	30 mg/m3	1,300 mg/m3	7,700 mg/m3
monoisobutanolamine	17 mg/m3	190 mg/m3	570 mg/m3

Ingredient	Original IDLH	Revised IDLH
butyl acrylate/ methyl methacrylate/ methacrylic acid pol.	Not Available	Not Available
titanium dioxide	5,000 mg/m3	Not Available
dolomite	Not Available	Not Available
2,2,4-trimethyl-1,3-pentanediol monoisobutyrate	Not Available	Not Available
acrylic acid, sodium salt	Not Available	Not Available
polypropylene glycol monobutyl ether	Not Available	Not Available
polyethylene glycol	Not Available	Not Available
monoisobutanolamine	Not Available	Not Available
superphosphates, concentrated	Not Available	Not Available
water	Not Available	Not Available

Occupational Exposure Banding

Ingredient	Occupational Exposure Band Rating	Occupational Exposure Band Limit
acrylic acid, sodium salt	E	≤ 0.01 mg/m³
monoisobutanolamine	E	≤ 0.01 mg/m³
Notes:	*Occupational exposure banding is a process of assigning chemicals into specific categories or bands based on a chemical's potency and the adverse health outcomes associated with exposure. The output of this process is an occupational exposure band (OEB), which corresponds to a range of exposure concentrations that are expected to protect worker health.*	

MATERIAL DATA

Exposure controls

Appropriate engineering controls	Engineering controls are used to remove a hazard or place a barrier between the worker and the hazard. Well-designed engineering controls can be highly effective in protecting workers and will typically be independent of worker interactions to provide this high level of protection. The basic types of engineering controls are: Process controls which involve changing the way a job activity or process is done to reduce the risk. Enclosure and/or isolation of emission source which keeps a selected hazard "physically" away from the worker and ventilation that strategically "adds" and "removes" air in the work environment. Ventilation can remove or dilute an air contaminant if designed properly. The design of a ventilation system must match the particular process and chemical or contaminant in use. Employers may need to use multiple types of controls to prevent employee overexposure.

Continued...

	Local exhaust ventilation usually required. If risk of overexposure exists, wear approved respirator. Correct fit is essential to obtain adequate protection. Supplied-air type respirator may be required in special circumstances. Correct fit is essential to ensure adequate protection. An approved self contained breathing apparatus (SCBA) may be required in some situations. Provide adequate ventilation in warehouse or closed storage area. Air contaminants generated in the workplace possess varying "escape" velocities which, in turn, determine the "capture velocities" of fresh circulating air required to effectively remove the contaminant.

Type of Contaminant:	Air Speed:
solvent, vapours, degreasing etc., evaporating from tank (in still air).	0.25-0.5 m/s (50-100 f/min.)
aerosols, fumes from pouring operations, intermittent container filling, low speed conveyer transfers, welding, spray drift, plating acid fumes, pickling (released at low velocity into zone of active generation)	0.5-1 m/s (100-200 f/min.)
direct spray, spray painting in shallow booths, drum filling, conveyer loading, crusher dusts, gas discharge (active generation into zone of rapid air motion)	1-2.5 m/s (200-500 f/min.)
grinding, abrasive blasting, tumbling, high speed wheel generated dusts (released at high initial velocity into zone of very high rapid air motion).	2.5-10 m/s (500-2000 f/min.)

Within each range the appropriate value depends on:

Lower end of the range	Upper end of the range
1: Room air currents minimal or favourable to capture	1: Disturbing room air currents
2: Contaminants of low toxicity or of nuisance value only.	2: Contaminants of high toxicity
3: Intermittent, low production.	3: High production, heavy use
4: Large hood or large air mass in motion	4: Small hood-local control only

Simple theory shows that air velocity falls rapidly with distance away from the opening of a simple extraction pipe. Velocity generally decreases with the square of distance from the extraction point (in simple cases). Therefore the air speed at the extraction point should be adjusted, accordingly, after reference to distance from the contaminating source. The air velocity at the extraction fan, for example, should be a minimum of 1-2 m/s (200-400 f/min) for extraction of solvents generated in a tank 2 meters distant from the extraction point. Other mechanical considerations, producing performance deficits within the extraction apparatus, make it essential that theoretical air velocities are multiplied by factors of 10 or more when extraction systems are installed or used.

Individual protection measures, such as personal protective equipment	
Eye and face protection	‣ Safety glasses with side shields. ‣ Chemical goggles. ‣ Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59], [AS/NZS 1336 or national equivalent]
Skin protection	See Hand protection below
Hands/feet protection	‣ Wear chemical protective gloves, e.g. PVC. ‣ Wear safety footwear or safety gumboots, e.g. Rubber
Body protection	See Other protection below
Other protection	‣ Overalls. ‣ P.V.C apron. ‣ Barrier cream. ‣ Skin cleansing cream. ‣ Eye wash unit.

Recommended material(s)

GLOVE SELECTION INDEX

Glove selection is based on a modified presentation of the:
"Forsberg Clothing Performance Index".
The effect(s) of the following substance(s) are taken into account in the ***computer-generated*** selection:
Jasart Byron Gesso

Material	CPI

Respiratory protection

Type AK-P Filter of sufficient capacity. (AS/NZS 1716 & 1715, EN 143:2000 & 149:2001, ANSI Z88 or national equivalent)

Where the concentration of gas/particulates in the breathing zone, approaches or exceeds the "Exposure Standard" (or ES), respiratory protection is required. Degree of protection varies with both face-piece and Class of filter; the nature of protection varies with Type of filter.

Required Minimum	Half-Face	Full-Face	Powered Air

Continued...

BUTYL	A
NEOPRENE	A
VITON	A
NATURAL RUBBER	C
PVA	C

* CPI - Chemwatch Performance Index
A: Best Selection
B: Satisfactory; may degrade after 4 hours continuous immersion
C: Poor to Dangerous Choice for other than short term immersion
NOTE: As a series of factors will influence the actual performance of the glove, a final selection must be based on detailed observation. -
* Where the glove is to be used on a short term, casual or infrequent basis, factors such as "feel" or convenience (e.g. disposability), may dictate a choice of gloves which might otherwise be unsuitable following long-term or frequent use. A qualified practitioner should be consulted.

Protection Factor	Respirator	Respirator	Respirator
up to 10 x ES	AK-AUS P2	-	AK-PAPR-AUS / Class 1 P2
up to 50 x ES	-	AK-AUS / Class 1 P2	-
up to 100 x ES	-	AK-2 P2	AK-PAPR-2 P2 ^

^ - Full-face
A(All classes) = Organic vapours, B AUS or B1 = Acid gasses, B2 = Acid gas or hydrogen cyanide(HCN), B3 = Acid gas or hydrogen cyanide(HCN), E = Sulfur dioxide(SO2), G = Agricultural chemicals, K = Ammonia(NH3), Hg = Mercury, NO = Oxides of nitrogen, MB = Methyl bromide, AX = Low boiling point organic compounds(below 65 degC)

· Respirators may be necessary when engineering and administrative controls do not adequately prevent exposures.
· The decision to use respiratory protection should be based on professional judgment that takes into account toxicity information, exposure measurement data, and frequency and likelihood of the worker's exposure - ensure users are not subject to high thermal loads which may result in heat stress or distress due to personal protective equipment (powered, positive flow, full face apparatus may be an option).
· Published occupational exposure limits, where they exist, will assist in determining the adequacy of the selected respiratory protection. These may be government mandated or vendor recommended.
· Certified respirators will be useful for protecting workers from inhalation of particulates when properly selected and fit tested as part of a complete respiratory protection program.
· Where protection from nuisance levels of dusts are desired, use type N95 (US) or type P1 (EN143) dust masks. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU)
· Use approved positive flow mask if significant quantities of dust becomes airborne.
· Try to avoid creating dust conditions.

SECTION 9 Physical and chemical properties

Information on basic physical and chemical properties

Appearance	White paste with slight odour, partly miscible in water.

Physical state	Free-flowing Paste	**Relative density (Water = 1)**	Not Available
Odour	Slight	**Partition coefficient n-octanol / water**	Not Available
Odour threshold	Not Available	**Auto-ignition temperature (°C)**	Not Available
pH (as supplied)	Not Available	**Decomposition temperature (°C)**	Not Available
Melting point / freezing point (°C)	Not Available	**Viscosity (cSt)**	Not Available
Initial boiling point and boiling range (°C)	Not Available	**Molecular weight (g/mol)**	Not Applicable
Flash point (°C)	Not Applicable	**Taste**	Not Available
Evaporation rate	Not Available	**Explosive properties**	Not Available
Flammability	Not Applicable	**Oxidising properties**	Not Available
Upper Explosive Limit (%)	Not Applicable	**Surface Tension (dyn/cm or mN/m)**	Not Available
Lower Explosive Limit (%)	Not Applicable	**Volatile Component (%vol)**	Not Available
Vapour pressure (kPa)	Not Available	**Gas group**	Not Available
Solubility in water	Partly miscible	**pH as a solution (1%)**	Not Available
Vapour density (Air = 1)	Not Available	**VOC g/L**	Not Available

Continued...

SECTION 10 Stability and reactivity

Reactivity	See section 7
Chemical stability	Product is considered stable and hazardous polymerisation will not occur.
Possibility of hazardous reactions	See section 7
Conditions to avoid	See section 7
Incompatible materials	See section 7
Hazardous decomposition products	See section 5

SECTION 11 Toxicological information

Information on toxicological effects

Inhaled	Evidence shows, or practical experience predicts, that the material produces irritation of the respiratory system, in a substantial number of individuals, following inhalation. In contrast to most organs, the lung is able to respond to a chemical insult by first removing or neutralising the irritant and then repairing the damage. The repair process, which initially evolved to protect mammalian lungs from foreign matter and antigens, may however, produce further lung damage resulting in the impairment of gas exchange, the primary function of the lungs. Respiratory tract irritation often results in an inflammatory response involving the recruitment and activation of many cell types, mainly derived from the vascular system. Inhalation of vapours may cause drowsiness and dizziness. This may be accompanied by narcosis, reduced alertness, loss of reflexes, lack of coordination and vertigo. Inhalation of dusts, generated by the material, during the course of normal handling, may be harmful.
Ingestion	The material has **NOT** been classified by EC Directives or other classification systems as "harmful by ingestion". This is because of the lack of corroborating animal or human evidence. The material may still be damaging to the health of the individual, following ingestion, especially where pre-existing organ (e.g liver, kidney) damage is evident. Present definitions of harmful or toxic substances are generally based on doses producing mortality rather than those producing morbidity (disease, ill-health). Gastrointestinal tract discomfort may produce nausea and vomiting. In an occupational setting however, ingestion of insignificant quantities is not thought to be cause for concern.
Skin Contact	The material produces mild skin irritation; evidence exists, or practical experience predicts, that the material either ▸ produces mild inflammation of the skin in a substantial number of individuals following direct contact, and/or ▸ produces significant, but mild, inflammation when applied to the healthy intact skin of animals (for up to four hours), such inflammation being present twenty-four hours or more after the end of the exposure period. Skin irritation may also be present after prolonged or repeated exposure; this may result in a form of contact dermatitis (nonallergic). The dermatitis is often characterised by skin redness (erythema) and swelling (oedema) which may progress to blistering (vesiculation), scaling and thickening of the epidermis. At the microscopic level there may be intercellular oedema of the spongy layer of the skin (spongiosis) and intracellular oedema of the epidermis. Skin contact is not thought to have harmful health effects (as classified under EC Directives); the material may still produce health damage following entry through wounds, lesions or abrasions. Repeated exposure may cause skin cracking, flaking or drying following normal handling and use. Open cuts, abraded or irritated skin should not be exposed to this material Entry into the blood-stream through, for example, cuts, abrasions, puncture wounds or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.
Eye	Evidence exists, or practical experience predicts, that the material may cause eye irritation in a substantial number of individuals and/or may produce significant ocular lesions which are present twenty-four hours or more after instillation into the eye(s) of experimental animals. Repeated or prolonged eye contact may cause inflammation characterised by a temporary redness (similar to windburn) of the conjunctiva (conjunctivitis); temporary impairment of vision and/or other transient eye damage/ulceration may occur.
Chronic	On the basis of epidemiological data, it has been concluded that prolonged inhalation of the material, in an occupational setting, may produce cancer in humans. Long-term exposure to respiratory irritants may result in disease of the airways involving difficult breathing and related systemic problems. Strong evidence exists that the substance may cause irreversible but non-lethal mutagenic effects following a single exposure. Serious damage (clear functional disturbance or morphological change which may have toxicological significance) is likely to be caused by repeated or prolonged exposure. As a rule the material produces, or contains a substance which produces severe lesions. Such damage may become apparent following direct application in subchronic (90 day) toxicity studies or following sub-acute (28 day) or chronic (two-year) toxicity tests. Limited evidence suggests that repeated or long-term occupational exposure may produce cumulative health effects involving organs or biochemical systems. On the basis, primarily, of animal experiments, concern has been expressed by at least one classification body that the material may produce carcinogenic or mutagenic effects; in respect of the available information, however, there presently exists inadequate data for making a satisfactory assessment.

Jasart Byron Gesso	**TOXICITY**	**IRRITATION**
	Not Available	Not Available

Continued...

butyl acrylate/ methyl methacrylate/ methacrylic acid pol.	**TOXICITY**	**IRRITATION**
	Not Available	Not Available
titanium dioxide	**TOXICITY**	**IRRITATION**
	dermal (hamster) LD50: >=10000 mg/kg[2]	Eye: no adverse effect observed (not irritating)[1]
	Inhalation(Rat) LC50: >2.28 mg/l4h[1]	Skin (human): 0.3 mg /3D (int)-mild *
	Oral (Rat) LD50: >=2000 mg/kg[1]	Skin: no adverse effect observed (not irritating)[1]
dolomite	**TOXICITY**	**IRRITATION**
	Not Available	Not Available
2,2,4-trimethyl-1,3-pentanediol monoisobutyrate	**TOXICITY**	**IRRITATION**
	dermal (guinea pig) LD50: >19 mg/kg[2]	Eye: no adverse effect observed (not irritating)[1]
	Oral (Rat) LD50: >3200 mg/kg[2]	Eyes - Moderate irritant *
		Skin - Slight irritant *
		Skin (rabbit): mild ***
		Skin: no adverse effect observed (not irritating)[1]
acrylic acid, sodium salt	**TOXICITY**	**IRRITATION**
	Dermal (rabbit) LD50: >2000 mg/kg[1]	Not Available
	Oral (Rat) LD50: >4000 mg/kg[1]	
polypropylene glycol monobutyl ether	**TOXICITY**	**IRRITATION**
	dermal (rat) LD50: >2000 mg/kg[1]	Skin (rabbit): 500 mg open - mild
	Oral (Rat) LD50: >300<2000 mg/kg[1]	
polyethylene glycol	**TOXICITY**	**IRRITATION**
	dermal (rat) LD50: >2000 mg/kg[1]	Eye (rabbit): 500mg/24h - mild.
	Oral (Rat) LD50: 600 mg/kg[2]	Eye: no adverse effect observed (not irritating)[1]
		Skin (rabbit): 500mg/24h - mild.
		Skin: no adverse effect observed (not irritating)[1]
monoisobutanolamine	**TOXICITY**	**IRRITATION**
	Dermal (rabbit) LD50: >2000 mg/kg[1]	Not Available
	Oral (Mouse) LD50; 2150 mg/kg[2]	
superphosphates, concentrated	**TOXICITY**	**IRRITATION**
	dermal (rat) LD50: >5000 mg/kg[1]	Not Available
	Inhalation(Rat) LC50: >2.6 mg/l4h[1]	
	Oral (Rat) LD50: >2000 mg/kg[1]	
water	**TOXICITY**	**IRRITATION**
	Oral (Rat) LD50: >90000 mg/kg[2]	Not Available
Legend:	*1. Value obtained from Europe ECHA Registered Substances - Acute toxicity 2. Value obtained from manufacturer's SDS. Unless otherwise specified data extracted from RTECS - Register of Toxic Effect of chemical Substances*	

TITANIUM DIOXIDE	* IUCLID Exposure to the material may result in a possible risk of irreversible effects. The material may produce mutagenic effects in man. This concern is raised, generally, on the basis of appropriate studies using mammalian somatic cells in vivo. Such findings are often supported by positive results from in vitro mutagenicity studies. For titanium dioxide: Humans can be exposed to titanium dioxide via inhalation, ingestion or dermal contact. In human lungs, the clearance kinetics of titanium dioxide is poorly characterized relative to that in experimental animals. (General particle characteristics and host factors that are considered to affect deposition and retention patterns of inhaled, poorly soluble particles such as titanium dioxide are summarized in the monograph on carbon black.) With regard to inhaled titanium dioxide, human data are mainly available from case reports that showed deposits of titanium dioxide in lung tissue as well as in lymph nodes. A single clinical study of oral

Continued...

	ingestion of fine titanium dioxide showed particle size-dependent absorption by the gastrointestinal tract and large interindividual variations in blood levels of titanium dioxide. Studies on the application of sunscreens containing ultrafine titanium dioxide to healthy skin of human volunteers revealed that titanium dioxide particles only penetrate into the outermost layers of the stratum corneum, suggesting that healthy skin is an effective barrier to titanium dioxide. There are no studies on penetration of titanium dioxide in compromised skin. Respiratory effects that have been observed among groups of titanium dioxide-exposed workers include decline in lung function, pleural disease with plaques and pleural thickening, and mild fibrotic changes. However, the workers in these studies were also exposed to asbestos and/or silica. No data were available on genotoxic effects in titanium dioxide-exposed humans. Many data on deposition, retention and clearance of titanium dioxide in experimental animals are available for the inhalation route. Titanium dioxide inhalation studies showed differences — both for normalized pulmonary burden (deposited mass per dry lung, mass per body weight) and clearance kinetics — among rodent species including rats of different size, age and strain. Clearance of titanium dioxide is also affected by pre-exposure to gaseous pollutants or co-exposure to cytotoxic aerosols. Differences in dose rate or clearance kinetics and the appearance of focal areas of high particle burden have been implicated in the higher toxic and inflammatory lung responses to intratracheally instilled vs inhaled titanium dioxide particles. Experimental studies with titanium dioxide have demonstrated that rodents experience dose-dependent impairment of alveolar macrophage-mediated clearance. Hamsters have the most efficient clearance of inhaled titanium dioxide. Ultrafine primary particles of titanium dioxide are more slowly cleared than their fine counterparts. Titanium dioxide causes varying degrees of inflammation and associated pulmonary effects including lung epithelial cell injury, cholesterol granulomas and fibrosis. Rodents experience stronger pulmonary effects after exposure to ultrafine titanium dioxide particles compared with fine particles on a mass basis. These differences are related to lung burden in terms of particle surface area, and are considered to result from impaired phagocytosis and sequestration of ultrafine particles into the interstitium. Fine titanium dioxide particles show minimal cytotoxicity to and inflammatory/pro-fibrotic mediator release from primary human alveolar macrophages in vitro compared with other particles. Ultrafine titanium dioxide particles inhibit phagocytosis of alveolar macrophages in vitro at mass dose concentrations at which this effect does not occur with fine titanium dioxide. In-vitro studies with fine and ultrafine titanium dioxide and purified DNA show induction of DNA damage that is suggestive of the generation of reactive oxygen species by both particle types. This effect is stronger for ultrafine than for fine titanium oxide, and is markedly enhanced by exposure to simulated sunlight/ultraviolet light. **Animal carcinogenicity data** Pigmentary and ultrafine titanium dioxide were tested for carcinogenicity by oral administration in mice and rats, by inhalation in rats and female mice, by intratracheal administration in hamsters and female rats and mice, by subcutaneous injection in rats and by intraperitoneal administration in male mice and female rats. In one inhalation study, the incidence of benign and malignant lung tumours was increased in female rats. In another inhalation study, the incidences of lung adenomas were increased in the high-dose groups of male and female rats. Cystic keratinizing lesions that were diagnosed as squamous-cell carcinomas but re-evaluated as non-neoplastic pulmonary keratinizing cysts were also observed in the high-dose groups of female rats. Two inhalation studies in rats and one in female mice were negative. Intratracheally instilled female rats showed an increased incidence of both benign and malignant lung tumours following treatment with two types of titanium dioxide. Tumour incidence was not increased in intratracheally instilled hamsters and female mice. In-vivo studies have shown enhanced micronucleus formation in bone marrow and peripheral blood lymphocytes of intraperitoneally instilled mice. Increased Hprt mutations were seen in lung epithelial cells isolated from titanium dioxide-instilled rats. In another study, no enhanced oxidative DNA damage was observed in lung tissues of rats that were intratracheally instilled with titanium dioxide. The results of most in-vitro genotoxicity studies with titanium dioxide were negative. The material may produce moderate eye irritation leading to inflammation. Repeated or prolonged exposure to irritants may produce conjunctivitis. **WARNING:** This substance has been classified by the IARC as Group 2B: Possibly Carcinogenic to Humans.
2,2,4-TRIMETHYL-1,3-PENTANEDIOL MONOISOBUTYRATE	Not a skin sensitiser (guinea pig, Magnusson-Kligman) *** Ames Test: negative *** Micronucleus, mouse: negative *** Not mutagenic *** No effects on fertility or foetal development seen in the rat *** * [SWIFT] ** [Eastman] *** [Perstop]
ACRYLIC ACID, SODIUM SALT	Based on the available oncogenicity data and without a better understanding of the carcinogenic mechanism the Health and Environmental Review Division (HERD), Office of Toxic Substances (OTS), of the US EPA previously concluded that all chemicals that contain the acrylate or methacrylate moiety (CH2=CHCOO or CH2=C(CH3)COO) should be considered to be a carcinogenic hazard unless shown otherwise by adequate testing. This position has now been revised and acrylates and methacrylates are no longer *de facto* carcinogens.
POLYPROPYLENE GLYCOL MONOBUTYL ETHER	for propylene glycol ethers (PGEs): Typical propylene glycol ethers include propylene glycol n-butyl ether (PnB); dipropylene glycol n-butyl ether (DPnB); dipropylene glycol methyl ether acetate (DPMA); tripropylene glycol methyl ether (TPM). Testing of a wide variety of propylene glycol ethers Testing of a wide variety of propylene glycol ethers has shown that propylene glycol-based ethers are less toxic than some ethers of the ethylene series. The common toxicities associated with the lower molecular weight homologues of the ethylene series, such as adverse effects on reproductive organs, the developing embryo and fetus, blood (haemolytic effects), or thymus, are not seen with the commercial-grade propylene glycol ethers. In the ethylene series, metabolism of the terminal hydroxyl group produces an alkoxyacetic acid. The reproductive and developmental toxicities of the lower molecular weight homologues in the ethylene series are due specifically to the formation of methoxyacetic and ethoxyacetic acids. Longer chain length homologues in the ethylene series are not associated with the reproductive toxicity but can cause haemolysis in sensitive species, also through formation of an alkoxyacetic acid. The predominant alpha isomer of all the PGEs (thermodynamically favored during manufacture of PGEs) is a secondary alcohol incapable of forming an alkoxypropionic acid. In contrast beta-isomers are able to form the alkoxypropionic acids and these are linked to teratogenic effects (and possibly haemolytic effects). This alpha isomer comprises greater than 95% of the isomeric mixture in the commercial product.

Continued...

	Because the alpha isomer cannot form an alkoxypropionic acid, this is the most likely reason for the lack of toxicity shown by the PGEs as distinct from the lower molecular weight ethylene glycol ethers. More importantly, however, very extensive empirical test data show that this class of commercial-grade glycol ether presents a low toxicity hazard. PGEs, whether mono, di- or tripropylene glycol-based (and no matter what the alcohol group), show a very similar pattern of low to non-detectable toxicity of any type at doses or exposure levels greatly exceeding those showing pronounced effects from the ethylene series. One of the primary metabolites of the propylene glycol ethers is propylene glycol, which is of low toxicity and completely metabolised in the body. As a class, the propylene glycol ethers are rapidly absorbed and distributed throughout the body when introduced by inhalation or oral exposure. Dermal absorption is somewhat slower but subsequent distribution is rapid. Most excretion for PGEs is via the urine and expired air. A small portion is excreted in the faeces. As a group PGEs exhibits low acute toxicity by the oral, dermal, and inhalation routes. Rat oral LD50s range from >3,000 mg/kg (PnB) to >5,000 mg/kg (DPMA). Dermal LD50s are all > 2,000 mg/kg (PnB, & DPnB; where no deaths occurred), and ranging up to >15,000 mg/kg (TPM). Inhalation LC50 values were higher than 5,000 mg/m3 for DPMA (4-hour exposure), and TPM (1-hour exposure). For DPnB the 4-hour LC50 is >2,040 mg/m3. For PnB, the 4-hour LC50 was >651 ppm (>3,412 mg/m3), representing the highest practically attainable vapor level. No deaths occurred at these concentrations. PnB and TPM are moderately irritating to eyes while the remaining category members are only slightly irritating to nonirritating. PnB is moderately irritating to skin while the remaining category members are slightly to non-irritating None are skin sensitisers. In repeated dose studies ranging in duration from 2 to 13 weeks, few adverse effects were found even at high exposure levels and effects that did occur were mild in nature. By the oral route of administration, NOAELs of 350 mg/kg-d (PnB – 13 wk) and 450 mg/kg-d (DPnB – 13 wk) were observed for liver and kidney weight increases (without accompanying histopathology). LOAELs for these two chemicals were 1000 mg/kg-d (highest dose tested). Dermal repeated-dose toxicity tests have been performed for many PGEs. For PnB, no effects were seen in a 13-wk study at doses as high as 1,000 mg/kg-d. A dose of 273 mg/kg-d constituted a LOAEL (increased organ weights without histopathology) in a 13-week dermal study for DPnB. For TPM, increased kidney weights (no histopathology) and transiently decreased body weights were found at a dose of 2,895 mg/kg-d in a 90-day study in rabbits. By inhalation, no effects were observed in 2-week studies in rats at the highest tested concentrations of 3244 mg/m3 (600 ppm) for PnB and 2,010 mg/m3 (260 ppm) for DPnB. TPM caused increased liver weights without histopathology by inhalation in a 2-week study at a LOAEL of 360 mg/m3 (43 ppm). In this study, the highest tested TPM concentration, 1010 mg/m3 (120 ppm), also caused increased liver weights without accompanying histopathology. Although no repeated-dose studies are available for the oral route for TPM, or for any route for DPMA, it is anticipated that these chemicals would behave similarly to other category members. One and two-generation reproductive toxicity testing has been conducted in mice, rats, and rabbits via the oral or inhalation routes of exposure on PM and PMA. In an inhalation rat study using PM, the NOAEL for parental toxicity is 300 ppm (1106 mg/m3) with decreases in body and organ weights occurring at the LOAEL of 1000 ppm (3686 mg/m3). For offspring toxicity the NOAEL is 1000 ppm (3686 mg/m3), with decreased body weights occurring at 3000 ppm (11058 mg/m3). For PMA, the NOAEL for parental and offspring toxicity is 1000 mg/kg/d. in a two generation gavage study in rats. No adverse effects were found on reproductive organs, fertility rates, or other indices commonly monitored in such studies. In addition, there is no evidence from histopathological data from repeated-dose studies for the category members that would indicate that these chemicals would pose a reproductive hazard to human health. In developmental toxicity studies many PGEs have been tested by various routes of exposure and in various species at significant exposure levels and show no frank developmental effects. Due to the rapid hydrolysis of DPMA to DPM, DPMA would not be expected to show teratogenic effects. At high doses where maternal toxicity occurs (e.g., significant body weight loss), an increased incidence of some anomalies such as delayed skeletal ossification or increased 13th ribs, have been reported. Commercially available PGEs showed no teratogenicity. The weight of the evidence indicates that propylene glycol ethers are not likely to be genotoxic. *In vitro*, negative results have been seen in a number of assays for PnB, DPnB, DPMA and TPM. Positive results were only seen in 3 out of 5 chromosome aberration assays in mammalian cells with DPnB. However, negative results were seen in a mouse micronucleus assay with DPnB and PM. Thus, there is no evidence to suggest these PGEs would be genotoxic *in vivo*. In a 2-year bioassay on PM, there were no statistically significant increases in tumors in rats and mice.
POLYETHYLENE GLYCOL	for molecular weights (200-8000) * Oral (rat) LD50: 31000->50000 mg/kg Oral (mice) LD50: 38000->50000 mg/kg Oral (g.pig) LD50: 17000->50000 mg/kg Oral (rabbit) LD50: 14000->50000 mg/kg * AIHA WEEL Guides Intraperitoneal (mice) LD50: 3100-12900 mg/kg for polyethylene glycols Pure polyethylene glycols have essentially similar toxicity, with toxicity being inverse to molecular weights. Absorption from the gastrointestinal tract decreases with increasing molecular weight The G.I. absorption of a series of polyethylene glycols has been studied. Polyethylene glycols having average molecular weights of 4000 and 6000 showed no absorption from the rat intestine over a five-hour period, while polyethylene glycols of 1000 and 1540 molecular weights showed a slight absorption amounting to less than 2% of the total dose during the same period. When 1 g doses of polyethylene glycols of molecular weight 1000 (PEG 1000) and 6000 (PEG 6000) were given intravenously to six human subjects, 85% of PEG 1000 and 96% of PEG 6000 were excreted in the urine in 12 hours. When these two same materials in 10 g doses were given orally to five human subjects, none of the PEG 6000 was found in the urine in the following 24 hours, whereas about 8% of PEG 1000 administered was found to excrete in urine within 24 hours When PEG 400 was given intravenously to three human subjects, an average of 77% recovery of this material was found in the urine in 12 hours. However, when the same substance was given orally to the same three human subjects, a recovery of between 40 and 50% of the dose was determined in the urine in the course of the following 24 hours. Single oral doses of PEG 400 were incompletely recovered from urine and faeces of rabbits even when collection of excreta was continued as long as four days following the dose. Evidence from all these and other studies indicate that ethylene glycol is not formed as a metabolite of PEG 400 Prolonged skin contact of PEG 1500 and 4000 upon the skin of rabbits in dosages of 10 g/kg bw showed no deleterious effects on internal organs and little, if any, of the materials was absorbed through the skin. Although early reports indicated that skin sensitization was observed among a few human subjects and in guinea pigs tested with certain polyethylene glycols, later studies showed that currently produced materials were without irritating or sensitizing properties. However, recent report (Fischer, 1978) demonstrated that four patients showed allergic reactions to lower molecular

Continued...

	weight liquid polyethylene glycols in topical medications. Two had immediate urticarial reactions to PEG 400. Two other patients had delayed allergic eczematous reactions, one to PEG 200, and one to PEG 300. Polyethers, for example, ethoxylated surfactants and polyethylene glycols, are highly susceptible towards air oxidation as the ether oxygens will stabilize intermediary radicals involved. Investigations of a chemically well-defined alcohol (pentaethylene glycol mono-n-dodecyl ether) ethoxylate, showed that polyethers form complex mixtures of oxidation products when exposed to air. Sensitization studies in guinea pigs revealed that the pure nonoxidized surfactant itself is nonsensitizing but that many of the investigated oxidation products are sensitizers. Two hydroperoxides were identified in the oxidation mixture, but only one (16-hydroperoxy-3,6,9,12,15-pentaoxaheptacosan-1-ol) was stable enough to be isolated. It was found to be a strong sensitizer in LLNA (local lymph node assay for detection of sensitization capacity). The formation of other hydroperoxides was indicated by the detection of their corresponding aldehydes in the oxidation mixture . On the basis of the lower irritancy, nonionic surfactants are often preferred to ionic surfactants in topical products. However, their susceptibility towards autoxidation also increases the irritation. Because of their irritating effect, it is difficult to diagnose ACD to these compounds by patch testing. Allergic Contact Dermatitis—Formation, Structural Requirements,and Reactivity of Skin Sensitizers. Ann-Therese Karlberg et al; Chem. Res. Toxicol.2008,21,53-69 Polyethylene glycols (PEGs) have a wide variety of PEG-derived mixtures due to their readily linkable terminal primary hydroxyl groups in combination with many possible compounds and complexes such as ethers, fatty acids, castor oils, amines, propylene glycols, among other derivatives. PEGs and their derivatives are broadly utilized in cosmetic products as surfactants, emulsifiers, cleansing agents, humectants, and skin conditioners. PEGs and PEG derivatives were generally regulated as safe for use in cosmetics, with the conditions that impurities and by-products, such as ethylene oxides and 1,4-dioxane, which are known carcinogenic materials, should be removed before they are mixed in cosmetic formulations. Most PEGs are commonly available commercially as mixtures of different oligomer sizes in broadly- or narrowly-defined molecular weight (MW) ranges. For instance, PEG-10,000 typically designates a mixture of PEG molecules (n = 195 to 265) having an average MW of 10,000. PEG is also known as polyethylene oxide (PEO) or polyoxyethylene (POE), with the three names being chemical synonyms. However, PEGs mainly refer to oligomers and polymers with molecular masses below 20,000 g/mol, while PEOs are polymers with molecular masses above 20,000 g/mol, and POEs are polymers of any molecular mass. Relatively small molecular weight PEGs are produced by the chemical reaction between ethylene oxide and water or ethylene glycol (or other ethylene glycol oligomers), as catalyzed by acidic or basic catalysts. To produce PEO or high-molecular weight PEGs, synthesis is performed by suspension polymerization. It is necessary to hold the growing polymer chain in solution during the course of the poly-condensation process. The reaction is catalyzed by magnesium-, aluminum-, or calcium-organoelement compounds. To prevent coagulation of polymer chains in the solution, chelating additives such as dimethylglyoxime are used Safety Evaluation of Polyethyene Glycol (PEG) Compounds for Cosmetic Use: Toxicol Res 2015; 31:105-136 The Korean Society of Toxicology http://doi.org/10.5487/TR.2015.31.2.105
MONOISOBUTANOLAMINE	For tris(hydroxymethyl)aminomethane (TRIS AMINO; CAS 77-88-1) and its surrogates 2-amino-2-methyl-1,3-propanediol (AMPD; CAS 115-69-5) and monoisobutanolamine (AMP; CAS 124-68-5) TRIS AMINO and the surrogate chemicals have displayed little if any toxicity to humans during their long history of use as human drugs and/or in personal care products and cosmetics. TRIS AMINO has found use as an IV drug for the management of acidosis in humans for many years and the toxicity of AMPD and AMP have been reviewed by the Cosmetic Ingredient Review Expert Panel which concluded that these materials are safe as used in cosmetic formulations up to 1% **Acute toxicity:** Mammalian toxicity studies have displayed similar results. The oral LD50 value for TRIS AMINO is 5500 mg/kg in the mouse, and its surrogates range from 2150 to greater than 5000 mg/kg in the rat and mouse. TRIS AMINO was non-irritating to eyes when a 40% aqueous solution was applied to the eyes of rabbits (pH 10.4 for 0.1M aqueous solution). In contrast, 95% AMP in water was severely irritating to the eyes, presumably due to the severely alkaline pH of the test solution used (pH 11.3 for 0.1M aqueous solution); however, more neutral cosmetic formulations containing lower concentrations of AMP are only minimally irritating. There is no sensitisation data available for TRIS AMINO; however, based on the following data, TRIS AMINO is not expected to be a sensitiser. Laboratory animal test samples of AMP did not cause allergic skin reactions when tested in guinea pigs following topical or intradermal administration. In patch tests with humans, AMP and cosmetic formulations containing either AMP or AMPD were negative for dermal sensitisation. **Repeated dose toxicity**: Repeated-dose mammalian toxicity studies conducted on TRIS AMINO and the two surrogate chemicals indicate that the compounds are generally well-tolerated at concentrations as high as 500 mg/kg/day via IV infusion for TRIS AMINO and ingestion of up to 3200 ppm in the rodent diet (250-750 mg/kg/day for rats and mice, estimated). A number of human clinical trials of the IV infusion of TRIS AMINO have also been successfully conducted. In all studies, the only target tissue, when observed at all, has been the liver with AMP. Human clinical studies with Keterolac(a major component of which is TRIS AMINO) have suggested that patients with decreased liver function not be given the drug over extended treatment periods based upon changes in several clinical chemistry parameters. Ingestion of relatively high dosages of AMP has caused liver histopathological changes in rats and dogs. The most significant toxicological activity has been a foetotoxic effect of AMP when ingested at relatively high levels by pregnant rats. Subsequent dermal exposure to comparable dosages failed to elicit a developmental effect in rats. Overall, there have been no consistently-noted observations or treatment-related findings among the numerous repeated-dose mammalian toxicity studies that have been conducted over at last 50 years on these compounds that would indicate long-term significant toxicity of either compound at typical human exposure levels. Reflective of these findings is the fact that both TRIS AMINO and AMP display similar patterns of excretion from the body, being primarily eliminated unchanged via the urine over a relatively short period of time. Further, no evidence of either direct reactivity or metabolism to reactive species toward genetic material has been observed. **Genetic toxicity:** Studies conducted on the TRIS AMINO and the surrogate substances in the presence or absence of mammalian metabolic enzymes have all been negative.
BUTYL ACRYLATE/ METHYL METHACRYLATE/ METHACRYLIC ACID POL. & TITANIUM DIOXIDE &	No significant acute toxicological data identified in literature search.

Continued...

DOLOMITE & ACRYLIC ACID, SODIUM SALT & SUPERPHOSPHATES, CONCENTRATED & WATER	
TITANIUM DIOXIDE & ACRYLIC ACID, SODIUM SALT	Asthma-like symptoms may continue for months or even years after exposure to the material ends. This may be due to a non-allergic condition known as reactive airways dysfunction syndrome (RADS) which can occur after exposure to high levels of highly irritating compound. Main criteria for diagnosing RADS include the absence of previous airways disease in a non-atopic individual, with sudden onset of persistent asthma-like symptoms within minutes to hours of a documented exposure to the irritant. Other criteria for diagnosis of RADS include a reversible airflow pattern on lung function tests, moderate to severe bronchial hyperreactivity on methacholine challenge testing, and the lack of minimal lymphocytic inflammation, without eosinophilia. RADS (or asthma) following an irritating inhalation is an infrequent disorder with rates related to the concentration of and duration of exposure to the irritating substance. On the other hand, industrial bronchitis is a disorder that occurs as a result of exposure due to high concentrations of irritating substance (often particles) and is completely reversible after exposure ceases. The disorder is characterized by difficulty breathing, cough and mucus production.
TITANIUM DIOXIDE & 2,2,4-TRIMETHYL-1,3-PENTANEDIOL MONOISOBUTYRATE & POLYPROPYLENE GLYCOL MONOBUTYL ETHER & POLYETHYLENE GLYCOL	The material may cause skin irritation after prolonged or repeated exposure and may produce a contact dermatitis (nonallergic). This form of dermatitis is often characterised by skin redness (erythema) and swelling epidermis. Histologically there may be intercellular oedema of the spongy layer (spongiosis) and intracellular oedema of the epidermis.
2,2,4-TRIMETHYL-1,3-PENTANEDIOL MONOISOBUTYRATE & POLYETHYLENE GLYCOL	The material may be irritating to the eye, with prolonged contact causing inflammation. Repeated or prolonged exposure to irritants may produce conjunctivitis.

Acute Toxicity	✗	**Carcinogenicity**	✓
Skin Irritation/Corrosion	✓	**Reproductivity**	✗
Serious Eye Damage/Irritation	✓	**STOT - Single Exposure**	✓
Respiratory or Skin sensitisation	✗	**STOT - Repeated Exposure**	✗
Mutagenicity	✓	**Aspiration Hazard**	✗

Legend: ✗ *– Data either not available or does not fill the criteria for classification*
✓ *– Data available to make classification*

SECTION 12 Ecological information

Toxicity

Jasart Byron Gesso

Endpoint	Test Duration (hr)	Species	Value	Source
Not Available	Not Available	Not Available	Not Available	Not Available

butyl acrylate/ methyl methacrylate/ methacrylic acid pol.

Endpoint	Test Duration (hr)	Species	Value	Source
Not Available	Not Available	Not Available	Not Available	Not Available

titanium dioxide

Endpoint	Test Duration (hr)	Species	Value	Source
BCF	1008h	Fish	<1.1-9.6	7
LC50	96h	Fish	1.85-3.06mg/l	4
EC50	72h	Algae or other aquatic plants	3.75-7.58mg/l	4
EC50	48h	Crustacea	1.9mg/l	2
EC50	96h	Algae or other aquatic plants	179.05mg/l	2
NOEC(ECx)	504h	Crustacea	0.02mg/l	4

dolomite

Endpoint	Test Duration (hr)	Species	Value	Source
Not Available	Not Available	Not Available	Not Available	Not Available

Continued...

2,2,4-trimethyl-1,3-pentanediol monoisobutyrate	**Endpoint**	**Test Duration (hr)**	**Species**	**Value**	**Source**
	NOEC(ECx)	72h	Algae or other aquatic plants	3.28mg/l	1
	EC50	72h	Algae or other aquatic plants	15mg/l	Not Available
	LC50	96h	Fish	16mg/l	Not Available
	EC50	48h	Crustacea	>19mg/l	2
acrylic acid, sodium salt	**Endpoint**	**Test Duration (hr)**	**Species**	**Value**	**Source**
	EC10(ECx)	72h	Algae or other aquatic plants	0.01mg/l	2
	EC50	72h	Algae or other aquatic plants	0.04mg/l	2
	LC50	96h	Fish	27mg/l	2
	EC50	48h	Crustacea	95mg/l	2
polypropylene glycol monobutyl ether	**Endpoint**	**Test Duration (hr)**	**Species**	**Value**	**Source**
	EC50(ECx)	48h	Crustacea	89-101mg/L	4
	EC50	48h	Crustacea	89-101mg/L	4
	LC50	96h	Fish	48-52mg/L	4
polyethylene glycol	**Endpoint**	**Test Duration (hr)**	**Species**	**Value**	**Source**
	EC50(ECx)	48h	Crustacea	>100mg/l	2
	EC50	96h	Algae or other aquatic plants	>100mg/l	2
	LC50	96h	Fish	>100mg/l	2
	EC50	48h	Crustacea	>100mg/l	2
monoisobutanolamine	**Endpoint**	**Test Duration (hr)**	**Species**	**Value**	**Source**
	LC50	96h	Fish	100mg/l	1
	EC50	48h	Crustacea	193mg/l	1
	EC50	72h	Algae or other aquatic plants	402mg/l	2
	EC0(ECx)	48h	Crustacea	100mg/l	1
superphosphates, concentrated	**Endpoint**	**Test Duration (hr)**	**Species**	**Value**	**Source**
	NOEC(ECx)	96h	Fish	85.9mg/l	2
	EC50	72h	Algae or other aquatic plants	>87.6mg/l	2
	LC50	96h	Fish	>85.9mg/l	2
	EC50	48h	Crustacea	>100mg/l	2
water	**Endpoint**	**Test Duration (hr)**	**Species**	**Value**	**Source**
	Not Available	Not Available	Not Available	Not Available	Not Available
Legend:	*Extracted from 1. IUCLID Toxicity Data 2. Europe ECHA Registered Substances - Ecotoxicological Information - Aquatic Toxicity 4. US EPA, Ecotox database - Aquatic Toxicity Data 5. ECETOC Aquatic Hazard Assessment Data 6. NITE (Japan) - Bioconcentration Data 7. METI (Japan) - Bioconcentration Data 8. Vendor Data*				

May cause long-term adverse effects in the aquatic environment.
DO NOT discharge into sewer or waterways.

Persistence and degradability

Ingredient	Persistence: Water/Soil	Persistence: Air
titanium dioxide	HIGH	HIGH
2,2,4-trimethyl-1,3-pentanediol monoisobutyrate	LOW	LOW
polypropylene glycol monobutyl ether	HIGH	HIGH
polyethylene glycol	LOW	LOW
monoisobutanolamine	LOW	LOW

Continued...

Ingredient	Persistence: Water/Soil	Persistence: Air
water	LOW	LOW

Bioaccumulative potential

Ingredient	Bioaccumulation
titanium dioxide	LOW (BCF = 10)
2,2,4-trimethyl-1,3-pentanediol monoisobutyrate	LOW (LogKOW = 2.9966)
polypropylene glycol monobutyl ether	LOW (LogKOW = 1.4138)
polyethylene glycol	LOW (LogKOW = -1.1996)
monoisobutanolamine	LOW (BCF = 330)

Mobility in soil

Ingredient	Mobility
titanium dioxide	LOW (KOC = 23.74)
2,2,4-trimethyl-1,3-pentanediol monoisobutyrate	LOW (KOC = 22.28)
polypropylene glycol monobutyl ether	LOW (KOC = 10)
polyethylene glycol	HIGH (KOC = 1)
monoisobutanolamine	MEDIUM (KOC = 2.196)

SECTION 13 Disposal considerations

Waste treatment methods

Product / Packaging disposal	▸ Containers may still present a chemical hazard/ danger when empty. ▸ Return to supplier for reuse/ recycling if possible. Otherwise: ▸ If container can not be cleaned sufficiently well to ensure that residuals do not remain or if the container cannot be used to store the same product, then puncture containers, to prevent re-use, and bury at an authorised landfill. ▸ Where possible retain label warnings and SDS and observe all notices pertaining to the product. ▸ **DO NOT** allow wash water from cleaning or process equipment to enter drains. ▸ It may be necessary to collect all wash water for treatment before disposal. ▸ In all cases disposal to sewer may be subject to local laws and regulations and these should be considered first. ▸ Where in doubt contact the responsible authority. ▸ Recycle wherever possible or consult manufacturer for recycling options. ▸ Consult State Land Waste Authority for disposal. ▸ Bury or incinerate residue at an approved site. ▸ Recycle containers if possible, or dispose of in an authorised landfill.

SECTION 14 Transport information

Labels Required

Marine Pollutant	NO
HAZCHEM	Not Applicable

Land transport (ADG): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Air transport (ICAO-IATA / DGR): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Sea transport (IMDG-Code / GGVSee): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Transport in bulk according to Annex II of MARPOL and the IBC code

Not Applicable

Continued...

Transport in bulk in accordance with MARPOL Annex V and the IMSBC Code

Product name	Group
butyl acrylate/ methyl methacrylate/ methacrylic acid pol.	Not Available
titanium dioxide	Not Available
dolomite	Not Available
2,2,4-trimethyl-1,3-pentanediol monoisobutyrate	Not Available
acrylic acid, sodium salt	Not Available
polypropylene glycol monobutyl ether	Not Available
polyethylene glycol	Not Available
monoisobutanolamine	Not Available
superphosphates, concentrated	Not Available
water	Not Available

Transport in bulk in accordance with the IGC Code

Product name	Ship Type
butyl acrylate/ methyl methacrylate/ methacrylic acid pol.	Not Available
titanium dioxide	Not Available
dolomite	Not Available
2,2,4-trimethyl-1,3-pentanediol monoisobutyrate	Not Available
acrylic acid, sodium salt	Not Available
polypropylene glycol monobutyl ether	Not Available
polyethylene glycol	Not Available
monoisobutanolamine	Not Available
superphosphates, concentrated	Not Available
water	Not Available

SECTION 15 Regulatory information

Safety, health and environmental regulations / legislation specific for the substance or mixture

butyl acrylate/ methyl methacrylate/ methacrylic acid pol. is found on the following regulatory lists

Australian Inventory of Industrial Chemicals (AIIC)

titanium dioxide is found on the following regulatory lists

Australian Inventory of Industrial Chemicals (AIIC)
Chemical Footprint Project - Chemicals of High Concern List
International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs
International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs - Group 2B: Possibly carcinogenic to humans
International WHO List of Proposed Occupational Exposure Limit (OEL) Values for Manufactured Nanomaterials (MNMS)

dolomite is found on the following regulatory lists

Australian Inventory of Industrial Chemicals (AIIC)

2,2,4-trimethyl-1,3-pentanediol monoisobutyrate is found on the following regulatory lists

Australian Inventory of Industrial Chemicals (AIIC)

acrylic acid, sodium salt is found on the following regulatory lists

Continued...

Australian Inventory of Industrial Chemicals (AIIC)

polypropylene glycol monobutyl ether is found on the following regulatory lists

Australian Inventory of Industrial Chemicals (AIIC)

polyethylene glycol is found on the following regulatory lists

Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 2
Australian Inventory of Industrial Chemicals (AIIC)
Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 3

monoisobutanolamine is found on the following regulatory lists

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals
Australian Inventory of Industrial Chemicals (AIIC)

superphosphates, concentrated is found on the following regulatory lists

Australian Inventory of Industrial Chemicals (AIIC)

water is found on the following regulatory lists

Australian Inventory of Industrial Chemicals (AIIC)

National Inventory Status

National Inventory	Status
Australia - AIIC / Australia Non-Industrial Use	Yes
Canada - DSL	No (acrylic acid, sodium salt; superphosphates, concentrated)
Canada - NDSL	No (butyl acrylate/ methyl methacrylate/ methacrylic acid pol.; 2,2,4-trimethyl-1,3-pentanediol monoisobutyrate; polypropylene glycol monobutyl ether; polyethylene glycol; monoisobutanolamine; water)
China - IECSC	Yes
Europe - EINEC / ELINCS / NLP	No (butyl acrylate/ methyl methacrylate/ methacrylic acid pol.)
Japan - ENCS	No (dolomite; superphosphates, concentrated)
Korea - KECI	Yes
New Zealand - NZIoC	Yes
Philippines - PICCS	No (superphosphates, concentrated)
USA - TSCA	Yes
Taiwan - TCSI	No (superphosphates, concentrated)
Mexico - INSQ	No (butyl acrylate/ methyl methacrylate/ methacrylic acid pol.; acrylic acid, sodium salt; polypropylene glycol monobutyl ether; polyethylene glycol; superphosphates, concentrated)
Vietnam - NCI	Yes
Russia - FBEPH	No (acrylic acid, sodium salt; superphosphates, concentrated)
Legend:	*Yes = All CAS declared ingredients are on the inventory* *No = One or more of the CAS listed ingredients are not on the inventory. These ingredients may be exempt or will require registration.*

SECTION 16 Other information

Revision Date	24/02/2023
Initial Date	24/02/2023

Other information

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

Definitions and abbreviations

PC—TWA: Permissible Concentration-Time Weighted Average

Continued...

PC—STEL: Permissible Concentration-Short Term Exposure Limit
IARC: International Agency for Research on Cancer
ACGIH: American Conference of Governmental Industrial Hygienists
STEL: Short Term Exposure Limit
TEEL: Temporary Emergency Exposure Limit。
IDLH: Immediately Dangerous to Life or Health Concentrations
ES: Exposure Standard
OSF: Odour Safety Factor
NOAEL :No Observed Adverse Effect Level
LOAEL: Lowest Observed Adverse Effect Level
TLV: Threshold Limit Value
LOD: Limit Of Detection
OTV: Odour Threshold Value
BCF: BioConcentration Factors
BEI: Biological Exposure Index
AIIC: Australian Inventory of Industrial Chemicals
DSL: Domestic Substances List
NDSL: Non-Domestic Substances List
IECSC: Inventory of Existing Chemical Substance in China
EINECS: European INventory of Existing Commercial chemical Substances
ELINCS: European List of Notified Chemical Substances
NLP: No-Longer Polymers
ENCS: Existing and New Chemical Substances Inventory
KECI: Korea Existing Chemicals Inventory
NZIoC: New Zealand Inventory of Chemicals
PICCS: Philippine Inventory of Chemicals and Chemical Substances
TSCA: Toxic Substances Control Act
TCSI: Taiwan Chemical Substance Inventory
INSQ: Inventario Nacional de Sustancias Químicas
NCI: National Chemical Inventory
FBEPH: Russian Register of Potentially Hazardous Chemical and Biological Substances